Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00320489 · ClinicalTrials.gov registry record · Phase 3
Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 524
- Enrollment target
NCT00320489 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 524 participants.
The verdict
NCT00320489, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 524 participants
- Enrollment target
Study Summary
To compare the health outcome of patients with schizophrenia, who are at risk for relapse, when treated with a long acting injection form of olanzapine versus treatment with oral olanzapine.
Interventions
- DRUG olanzapine
- DRUG olanzapine pamoate depot
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 524 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00320489
The ClinicalTrials.gov registry entry for NCT00320489 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 524 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which olanzapine is the first listed.
NCT00320489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00320489 about?
NCT00320489 is a clinical study titled "Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia". To compare the health outcome of patients with schizophrenia, who are at risk for relapse, when treated with a long acting injection form of olanzapine versus treatment with oral olanzapine.
What is the current status of trial NCT00320489?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 524 participants. The study started on 2006-04. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00320489?
The interventions under investigation include: olanzapine (DRUG), olanzapine pamoate depot (DRUG).
Who is sponsoring clinical trial NCT00320489?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.